Published in N Engl J Med on March 15, 2001
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis (2013) 3.56
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis. Cost Eff Resour Alloc (2006) 2.83
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA (2016) 2.23
HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med (2012) 2.21
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care (2007) 2.06
Cost effectiveness analysis in health care: contraindications. BMJ (2002) 1.80
The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol (2005) 1.76
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS (2008) 1.59
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS (2012) 1.57
Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One (2010) 1.46
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med (2005) 1.42
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clin Infect Dis (2015) 1.40
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med (2012) 1.29
Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med (2013) 1.28
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS (2012) 1.26
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis (2012) 1.14
Adherence counseling practices of generalist and specialist physicians caring for people living with HIV/AIDS in North Carolina. J Gen Intern Med (2004) 1.11
Financial burden of health services for people with HIV/AIDS in India. Indian J Med Res (2007) 1.09
Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One (2014) 1.07
Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners. Public Health Rep (2007) 1.06
Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. J Acquir Immune Defic Syndr (2013) 1.04
Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine (2009) 1.01
The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend (2012) 1.01
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res (2013) 1.00
Should we treat acute HIV infection? Curr HIV/AIDS Rep (2012) 1.00
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials (2010) 1.00
The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr (2007) 0.98
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr (2009) 0.96
Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV. Drug Alcohol Depend (2008) 0.96
HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PLoS One (2011) 0.94
Providing antiretroviral therapy for HIV infection. N Engl J Med (2001) 0.92
The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy (2008) 0.92
The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med (2007) 0.92
Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One (2014) 0.91
Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med (2011) 0.89
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag (2012) 0.89
Cost-effectiveness analysis and HIV screening: the emergency medicine perspective. Ann Emerg Med (2011) 0.89
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther (2012) 0.88
Factors associated with improvement in disability-adjusted life years in patients with HIV/AIDS. BMC Public Health (2008) 0.88
A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa. PLoS One (2013) 0.88
The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis (2015) 0.88
The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One (2012) 0.86
Difficulties reported by HIV-infected patients using antiretroviral therapy in Brazil. Clinics (Sao Paulo) (2008) 0.86
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS (2011) 0.86
Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009. Health Aff (Millwood) (2014) 0.85
Use of dynamic microsimulation to predict disease progression in patients with pneumonia-related sepsis. Crit Care (2007) 0.84
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials (2012) 0.84
Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (2003) 0.84
Conservation of biodiversity as a strategy for improving human health and well-being. Philos Trans R Soc Lond B Biol Sci (2017) 0.84
Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. Value Health (2010) 0.83
Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS One (2013) 0.83
In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother (2003) 0.83
Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. J Infect Dis (2016) 0.82
The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model. Ophthalmology (2012) 0.82
Cost-effective control of chronic viral diseases: finding the optimal level of screening and contact tracing. Math Biosci (2010) 0.82
Keeping the noise down: common random numbers for disease simulation modeling. Health Care Manag Sci (2008) 0.82
Age-dependent cost-utility of pediatric cochlear implantation. Ear Hear (2013) 0.81
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag (2013) 0.81
How HIV treatment could result in effective prevention. Future Virol (2010) 0.80
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics (2015) 0.80
A stochastic multi-scale model of HIV-1 transmission for decision-making: application to a MSM population. PLoS One (2013) 0.79
CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther (2010) 0.79
Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One (2010) 0.79
Short-Term Rationing of Combination Antiretroviral Therapy: Impact on Morbidity, Mortality, and Loss to Follow-Up in a Large HIV Treatment Program in Western Kenya. AIDS Res Treat (2012) 0.78
Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy. Antimicrob Agents Chemother (2012) 0.78
Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS One (2011) 0.78
The cost effectiveness of antiretroviral therapy for HIV disease. N Engl J Med (2001) 0.78
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire. J Acquir Immune Defic Syndr (2014) 0.77
Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. PLoS One (2012) 0.77
Using mechanistic models to simulate comparative effectiveness trials of therapy and to estimate long-term outcomes in HIV care. Med Care (2010) 0.76
Determining the Cost-Savings Threshold for HIV Adherence Intervention Studies for Persons with Serious Mental Illness and HIV. Community Ment Health J (2014) 0.76
Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther (2010) 0.76
Clinical endpoints in trials of drugs for cancer: time for a rethink? BMJ (2002) 0.76
Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. Health Care Financ Rev (2005) 0.76
Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One (2013) 0.75
HIV Treatment in Resource-Limited Environments: Treatment Coverage and Insights. Value Health (2015) 0.75
Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med (2011) 0.75
Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics (2016) 0.75
The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. J Virus Erad (2015) 0.75
Impact of Antiretroviral Therapy on the Spread of Human Immunodeficiency Virus in Chaoyang District, Beijing, China: Using the Asian Epidemic Model. Chin Med J (Engl) (2017) 0.75
Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis. Subst Abuse Treat Prev Policy (2017) 0.75
The sequence of the human genome. Science (2001) 101.55
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
Performance of a five-item mental health screening test. Med Care (1991) 8.76
Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med (1977) 8.60
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 8.52
Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol (2000) 7.77
Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States medicare population. J Bone Joint Surg Am (2001) 7.67
Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal (1995) 7.45
Extreme discordant sib pairs for mapping quantitative trait loci in humans. Science (1995) 7.00
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 6.80
Ecological degradation in protected areas: the case of Wolong Nature Reserve for giant pandas. Science (2001) 6.52
Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med (2001) 6.01
D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell (1992) 5.51
p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol (1999) 5.40
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA (1997) 5.36
Lidocaine block of cardiac sodium channels. J Gen Physiol (1983) 5.13
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
The cost of a successful delivery with in vitro fertilization. N Engl J Med (1994) 4.94
Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis (2001) 4.94
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci U S A (2001) 4.79
Structure of the gene V protein of bacteriophage f1 determined by multiwavelength x-ray diffraction on the selenomethionyl protein. Proc Natl Acad Sci U S A (1994) 4.67
DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell (1995) 4.64
Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis. Arch Gen Psychiatry (1987) 4.62
Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res (1992) 4.58
Familial transmission of substance use disorders. Arch Gen Psychiatry (1998) 4.57
Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making (1985) 4.47
Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med (1998) 4.47
Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med (1980) 4.45
Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A (1996) 4.20
Aggregation-based crystal growth and microstructure development in natural iron oxyhydroxide biomineralization products. Science (2000) 4.03
Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation (1991) 3.75
Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev (1993) 3.70
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell (2001) 3.66
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
The DISC Predictive Scales (DPS): efficiently screening for diagnoses. J Am Acad Child Adolesc Psychiatry (2001) 3.52
Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med (1998) 3.47
Sorting of beta-actin mRNA and protein to neurites and growth cones in culture. J Neurosci (1998) 3.45
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci U S A (1997) 3.42
PKS1, a substrate phosphorylated by phytochrome that modulates light signaling in Arabidopsis. Science (1999) 3.42
Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health (1985) 3.31
Microcolinearity in sh2-homologous regions of the maize, rice, and sorghum genomes. Proc Natl Acad Sci U S A (1997) 3.29
Clinical outcomes and costs of transcatheter as compared with surgical closure of patent ductus arteriosus. The Patient Ductus Arteriosus Closure Comparative Study Group. N Engl J Med (1993) 3.27
Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A (1998) 3.26
Erythropoietin response is blunted in critically ill patients. Intensive Care Med (1997) 3.20
Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A (1997) 3.19
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J (1999) 3.13
Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. Nature (1995) 3.06
Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med (1980) 3.03
Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci (2000) 3.00
Socioeconomic status and type 2 diabetes in African American and non-Hispanic white women and men: evidence from the Third National Health and Nutrition Examination Survey. Am J Public Health (2001) 2.96
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature (1997) 2.93
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis (2001) 2.85
Use and misuse of the term "cost effective" in medicine. N Engl J Med (1986) 2.82
An information-based sequence distance and its application to whole mitochondrial genome phylogeny. Bioinformatics (2001) 2.80
Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med (1989) 2.77
Course of tic severity in Tourette syndrome: the first two decades. Pediatrics (1998) 2.75
Medical decision support: experience with implementing the Arden Syntax at the Columbia-Presbyterian Medical Center. Proc Annu Symp Comput Appl Med Care (1995) 2.74
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med (2000) 2.71
The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA (1998) 2.69
Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med (1987) 2.64
Interaction of short-range repressors with Drosophila CtBP in the embryo. Science (1998) 2.61
Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med (1996) 2.60
Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry (2001) 2.59
Pseudobacteremia caused by povidone-iodine solution contaminated with Pseudomonas cepacia. N Engl J Med (1981) 2.56
Receptor-mediated hydrolysis of plasma membrane messenger PIP2 leads to K+-current desensitization. Nat Cell Biol (2000) 2.55
Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. N Engl J Med (1977) 2.54
Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis (2001) 2.53
When doctors meet numbers. Am J Med (1981) 2.48
Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med (2001) 2.47
A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health (1988) 2.46
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Barriers to using cost-effectiveness analysis in managed care decision making. Am J Manag Care (2000) 2.41
BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene (1998) 2.39
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA (1999) 2.35
Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA (1992) 2.32
Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci U S A (1999) 2.30
A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry (1998) 2.27
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology (2000) 2.26
Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med (1991) 2.25
Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med (1992) 2.25
Simple sequence repeats in Escherichia coli: abundance, distribution, composition, and polymorphism. Genome Res (2000) 2.24